Skip to main content
MNKD logo

MNKD · Mannkind Corp · Documents

Track MNKD — free
$4.04 +0.09 (+2.28%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.27B
Shares
321.64M
Volume · Nov 20 457.44K Avg daily vol (3M) 3.94M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $348.97M up 22.2% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $101.87M up 24.0% 10-Q filed Nov 5, 2026 Latest results Revenue rises 24% as Furoscix ReadyFlow gains adoption 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 18
Investor event
Q4 revenue expected at about $38 million, plus or minus

Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback.

4 source passages
We expect Q4 to be about $38 million in revenue. It'll be plus or minus. That trial has now been the foundation with the FDA to advance into Phase 2 here in the U.S. We just met with the FDA. Open the document at this passage
Nov 5
Earnings call
ReadyFlow adoption accelerates as fourth-quarter profitability nears

Mankind Corporation reported third-quarter revenue of $101.9 million, up 24%, while roughly 75% of Furosix shipments had moved to ReadyFlow by late October. It expects record fourth-quarter revenue to drive profitability.

3 source passages
Third quarter total revenue was $101.9 million, up 24%, from $82.1 million in the third quarter of 2025. Furosix ReadyFlow was approved and by late October, roughly 75% of Furosix shipments had moved to ReadyFlow, exceeding our internal expectations by several quarters. We expect record revenue in Q4 will drive us to profitability as we close out the year Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 27% as net loss reached $58.9 million

For the nine months ended September 30, 2026, Mannkind reported 27% total revenue growth, a $58.9 million net loss and a $36.9 million, or 73%, increase in commercial product gross profit.

Revenue $101.87M ▲ 24.0% Net loss $23.22M Diluted EPS -$0.07
Read from the MD&A section
4 source passages
### Three and nine months ended September 30, 2026 and 2025 Total revenues | 301,416 | 237,011 | 64,405 | | 27% Cash used in operating activities consisted of a net loss of $58.9 million offset by non-cash adjustments of $58.8 million and a net decrease in cash flow from operating assets and liabilities of $58.2 million. Commercial product gross profit increased by $36.9 million, or 73%, for the nine months ended September 30, 2026 compared to the same period in the prior year. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 24% as Furoscix ReadyFlow gains adoption

MannKind reported Q3 2026 total revenues of $101.9 million, up 24% from Q3 2025, as commercial product revenue reached $45.0 million. Furoscix ReadyFlow shipments began in mid-September and represented approximately 75% of current weekly Furoscix shipments.

Financial results
4 source passages
Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 Furoscix ReadyFlow was approved and shipments commenced mid-September Rapid adoption of Furoscix ReadyFlow, making up approximately 75% of the current weekly Furoscix shipments Open the document at this passage
Oct 20
Investor event
Chardan Healthcare Conference

Mannkind said inhaled natetanib is entering phase 2 with about 140 patients testing two doses in about 12 or 13 countries, after initial dosing showed no diarrhea or cough-related discontinuations.

Aug 21
Current report 8-K
Other events AI summary on its way
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $109.37M ▲ 42.9% Net loss $19.03M Diluted EPS -$0.06
Jun 2
Current report 8-K Events of May 29
Other events AI summary on its way
May 28
Current report 8-K Events of May 27
Other events AI summary on its way
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $90.17M ▲ 15.1% Net loss $16.62M Diluted EPS -$0.05
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $348.97M ▲ 22.2% Net income $5.86M ▼ 78.7% Diluted EPS $0.02 ▼ 80.0%
2025
Nov 5
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $82.13M ▲ 17.2% Net income $7.99M ▼ 30.9% Diluted EPS $0.03 ▼ 25.0%
May 8
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $78.35M ▲ 18.2% Net income $13.16M ▲ 23.8% Diluted EPS $0.04 ▲ unchanged
Showing 1–50 of 168 documents
Key facts CIK 899460 CUSIP 56400P706 13F (30d) 262 filings 232 filers Visit website Investor relations